Drugs / ONZIGOLIDE
ONZIGOLIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01018953 | Feb → Dec 2010 | carcinoid syndrome | Ipsen | Terminated | No outcome recorded |
| Phase 2 | NCT00994214 | Oct 2009 → Feb 2011 | acromegaly | Ipsen | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04335357 Comparator | May 2020 → Mar 2023 | non-functioning pituitary adenoma | Tiburio Therapeutics | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONZIGOLIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650342 ↗ |
| Known as | BIM 23A760 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00994214 ↗ |
| Known as | Dopastatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650342 ↗ |
| Known as | TBR-760 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04335357 ↗ |
| Action | Activate | “chimeric dopamine-somatostatin receptor agonist” NCT04335357 ↗3“Somatostatin receptor 2 agonist” CHEMBL4650342 ↗ “Somatostatin receptor 5 agonist” CHEMBL4650342 ↗ “Dopamine D2 receptor agonist” CHEMBL4650342 ↗ |
| Modality | Other / unclassified | “chimeric dopamine-somatostatin receptor agonist” NCT04335357 ↗ |
| Route | Subcutaneous | “Subcutaneous injections of BIM23A760 once a week.” NCT00994214 ↗ |
| Target | DRD2 | “Dopamine D2 receptor agonist” CHEMBL4650342 ↗ |
| Target | SSTR2 | “Somatostatin receptor 2 agonist” CHEMBL4650342 ↗ |
| Target | SSTR5 | “Somatostatin receptor 5 agonist” CHEMBL4650342 ↗ |